Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Asia Pacific Antifungal Drugs Market: By Product Type, By Dosage Forms, By Application By Distribution Channel, and Country
Asia Pacific Antifungal Drugs Market size was valued at US$ 2,600.0 million in 2022 and is expected to reach US$ 3,421.4 million by 2028, at a CAGR of 4% from 2023-2029. The majority of fatal fungal infections affect people with weakened immune systems, including those affected by HIV/AIDS, cancer treatment, and hematology, among other conditions. Another significant reason boosting demand for antifungal medications is the rising prevalence of immunodeficiency disorders and invasive fungal infections. The ease of use of antifungal medicines, including oral pills, topical creams and ointments, IV drips, and over-the-counter pharmaceuticals, is another important reason driving up demand for antifungal medications in the healthcare industry. Additionally, the market is expanding as a result of increased R&D for newly developed drugs designed to treat fungal infections.
The major factors driving the market are rising awareness of fungal infections with the increasing antifungal infections all over the world, rising government and corporate funding in the industry.
Report Benchmarks |
Details |
Market Size in 2022 |
US$ 2,600.0 million |
Market Size in 2028 |
US$ 3,421.4 million |
By Product Type |
|
By Dosage Forms |
|
By Application |
|
By Distribution Channel |
|
Download Free Sample Report
The asia pacific antifungal drugs market size was valued at US$ 2,600.0 million in 2022
The report covers the countries market data: China, India, Japan, Australia & New Zealand
Astellas Pharma, Inc. (Japan) Bayer AG (Germany) Enzon Pharmaceuticals, Inc. (U.S.) GlaxoSmithKline plc. (U.K.) Merck & Co., Inc. (U.S.) Novartis AG (Switzerland)
Key Market Players